Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김완규 | * |
dc.contributor.author | 이해승 | * |
dc.date.accessioned | 2019-01-24T16:30:14Z | - |
dc.date.available | 2019-01-24T16:30:14Z | - |
dc.date.issued | 2018 | * |
dc.identifier.issn | 1476-4598 | * |
dc.identifier.other | OAK-24129 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/248254 | - |
dc.description.abstract | Even when targets responsible for chemoresistance are identified, drug development is often hampered due to the poor druggability of these proteins. We systematically analyzed therapy-resistance with a large-scale cancer cell transcriptome and drug-response datasets and predicted the candidate drugs based on the gene expression profile. Our results implicated the epithelial-mesenchymal transition as a common mechanism underlying resistance to chemotherapeutic drugs. Notably, we identified ITGB3, whose expression was abundant in both drug resistance and mesenchymal status, as a promising target to overcome chemoresistance. We also confirmed that depletion of ITGB3 sensitized cancer cells to conventional chemotherapeutic drugs by modulating the NF-B signaling pathway. Considering the poor druggability of ITGB3 and the lack of feasible drugs to directly inhibit this protein, we took an in silico screening for drugs mimicking the transcriptome-level changes caused by knockdown of ITGB3. This approach successfully identified atorvastatin as a novel candidate for drug repurposing, paving an alternative path to drug screening that is applicable to undruggable targets. | * |
dc.language | English | * |
dc.publisher | BMC | * |
dc.subject | Chemoresistance | * |
dc.subject | Mesenchymal cancer | * |
dc.subject | Pharmacogenomics | * |
dc.subject | Drug repurposing | * |
dc.subject | Biomarker | * |
dc.subject | ITGB3 | * |
dc.subject | NF-B | * |
dc.subject | Atorvastatin | * |
dc.subject | Systems pharmacology | * |
dc.title | Large-scale pharmacogenomics based drug discovery for ITGB3 dependent chemoresistance in mesenchymal lung cancer | * |
dc.type | Article | * |
dc.relation.volume | 17 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | MOLECULAR CANCER | * |
dc.identifier.doi | 10.1186/s12943-018-0924-8 | * |
dc.identifier.wosid | WOS:000453819700001 | * |
dc.identifier.scopusid | 2-s2.0-85058803103 | * |
dc.author.google | Hong, Soon-Ki | * |
dc.author.google | Lee, Haeseung | * |
dc.author.google | Kwon, Ok-Seon | * |
dc.author.google | Song, Na-Young | * |
dc.author.google | Lee, Hyo-Ju | * |
dc.author.google | Kang, Seungmin | * |
dc.author.google | Kim, Jeong-Hwan | * |
dc.author.google | Kim, Mirang | * |
dc.author.google | Kim, Wankyu | * |
dc.author.google | Cha, Hyuk-Jin | * |
dc.contributor.scopusid | 김완규(25627654100) | * |
dc.date.modifydate | 20240130091819 | * |